Skip to content

MACE and PE in Elective Primary TKA & THA

Registration of the Major Adverse Cardiovascular Events and Pulmonary Embolism in Primary Total Joint Arthroplasty

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05116280
Enrollment
200
Registered
2021-11-11
Start date
2018-01-01
Completion date
2019-01-30
Last updated
2021-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular Complication, Death, Pulmonary Embolism, Stroke, Transient Ischemic Attack

Keywords

total joint arthroplasty, total hip arthroplasty, total knee arthroplasty, major adverse cardiovascular events, pulmonary embolism

Brief summary

This study ought to identify the occurence of the major adverse cardiovascular events (MACE) and the pumonary emoblism (PE) in patients undergoing elective primary THA & TKA

Detailed description

The study included 220 consecutive patients undergoing elective primary THA & TKA from January 2018 to December 2018. The occcurence of major adverse cardiovascular events (MACE) and the pumonary emoblism (PE) were recorder. Under the term MACE the following were included; non fatal cardiac arrest acute myocardial infraction congestive cardiac failure cardiac arrhythmia agnina stroke cardiovascular death cerebrovascular death

Interventions

None listed

Sponsors

University of Thessaly
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* All consecutive patients age 18 years or older, with a diagnosis of primary osteoarthritis of the hip or knee, who underwent elective, primary, unilateral TKA or THA.

Exclusion criteria

* previous TKA or THA within 3 months * Revision surgery * Surgical procedures related to a previous complication * ASA PS IV * recent history (6 months) of unstable acute coronary syndrome or decompensated heart failure

Design outcomes

Primary

MeasureTime frameDescription
Major Adverse Cardiovascular Events1month postoperativelyMACE (non-fatal-cardiac arrest, acute myocardial infraction, congestive cardiac failure, cardiac arrhythmia, angina, stroke, cardiovascular death, cerebrovascular, death)
Pulmonary Embolism1month postoperativelyPE

Countries

Greece

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026